Mumbai February 10, 2013:- After the US Food and Drug Administration (USFDA) raised concerns over Ranbaxy’s largest drug ingredient plant at Toansa, many questions regarding the GMP compliance have come up. The company is making every attempt to investigate these issues and aims at resolving them.
During the company’s internal investigations, certain preliminary findings have called attention. These findings point towards a possibility that some of the good manufacturing practice (GMP) violations that the FDA inspectors observed at the Toansa plant could have been framed by some dissatisfied employees. This needs further investigations before concluding anything. – GMP
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…